1. N. M. Hoosein, M. K. McKnight, A. E. Levine, K. M. Mulder, K. E. Childress, D. E. Brattain, and M. G. Brattain (1989). Differential sensitivities of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of TGF-β1.Exp. Cell Res. 181:442–453.
2. A. M. Manning, A. C. Williams, S. M. Gurne, and C. Paraskeva (1991). Differential sensitivity of human colonic adenoma and carcinoma cells to TGF-β1. Conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to inhibiting affects of TGF-β.Oncogene 6:1471–1476.
3. S. Markowitz, L. Meyeroff, M. Cooper, J. Trascoff, M. Kochera, J. Lutterbaugh, M. Swiriduk, and J. K. V. Willson (1994). A benign cultured colon adenoma bears 3 genetically altered oncogenes, but progresses to tumorigenicity and TGF-β independence without inactivating the p53 tumor suppressor gene.J. Clin. Invest. 93:1005–1013.
4. C. L. Arteaga, A. K. Tandon, D. D. VonHoff, and C. K. Osborne (1988). TGF-β: Potential autocrine growth control inhibitor of estrogen receptor negative human breast cancer cells.Cancer Res. 48:3898–3904.
5. C. L. Arteaga, T. Carty-Dugger, H. C. Moses, S. D. Hurd, and J. A. Pietenpol (1993). TGF-β1 can induce estrogen independent tumorigenicity of human breast cancer cells in athymic mice.Cell Growth Differ. 4:193–201.